🔖
Cite This Article
DENG, Z., LIU, H., SU, J., LU, Y., ZHONG, J., TENG, Y. (2022). Prevalence of MAFLD-Related Hepatocellular Carcinoma. Eurasian Journal of Medicine and Oncology, Cilt: 6 - Sayı: 2, 190–191. https://ajindex.com/articles/509468
Journals / Eurasian Journal of Medicine and Oncology / 2022 / Cilt: 6 - Sayı: 2
Prevalence of MAFLD-Related Hepatocellular Carcinoma
- Pages
- 190–191
- Publication Date
- 2022-10-12
- DOI
- —
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗References (6)
- Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut. 2021 Dec 21. doi: 10.1136/gutjnl-2021-324915. [Epub ahead of print]
- Eslam M, Sanyal AJ, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999–2014.e1. [CrossRef] 3. Conci S, Cipriani F, Donadon M, Marchitelli I, Ardito F, Famularo S, et al; He.RC.O.Le.S Group. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol 2022;48:103–12. [CrossRef] 4. Liu L, Xie S, Teng YX, Deng ZJ, Chen K, Liu HT, et al. Outcomes of liver resection for metabolic dysfunction-associated fatty liver disease or chronic hepatitis B-related HCC. Front Oncol 2022;11:783339
- Xiong KG, Ke KY, Chen LF, Kong JF, Ling TS, Lin QB, et al. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection. Hepatobiliary Pancreat Dis Int. 2022 Apr 6. doi: 10.1016/j.hbpd.2022.1004.1001. [Epub ahead of print]
- Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, et al. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med 2021;11:684
- Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542–3565. [CrossRef] 8. Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol 2022;20:573–82. [CrossRef] 9. Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Högström S, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 2021;6:73–9
- Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020;73:202–9. [CrossRef]